Pittsburgh Compound B Unlabelled
Frontotemporal Dementia
Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Frontotemporal Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Flortaucipir Mayo Clinic | Phase 4 | BBB |
Fludeoxyglucose University of Michigan | Phase 4 | BB |
Citalopram Sunnybrook Health Sciences Centre | Phase 4 | BB |
Lemborexant Nova Scotia Health Authority | Phase 4 | BB |
Izaflortaucipir University of Pennsylvania | Phase 3 | BB |
View all 38 →
Same molecule, other indications
Pittsburgh Compound B Unlabelled is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →